Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
EPIX logo EPIX
Upturn stock ratingUpturn stock rating
EPIX logo

ESSA Pharma Inc (EPIX)

Upturn stock ratingUpturn stock rating
$0.24
Last Close (24-hour delay)
Profit since last BUY-54.91%
upturn advisory
SELL
SELL since 5 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

08/29/2025: EPIX (1-star) is a SELL. SELL since 5 days. Profits (-54.91%). Updated daily EoD!

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

2 Analysts rated it

Very few follow this stock; limited insights, higher-risk early investing.

1 Year Target Price $1.74

1 Year Target Price $1.74

Analysts Price Target For last 52 week
$1.74 Target price
52w Low $0.22
Current$0.24
52w High $7.88

Analysis of Past Performance

Type Stock
Historic Profit -32.87%
Avg. Invested days 41
Today’s Advisory SELL
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 2.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 08/29/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 11.35M USD
Price to earnings Ratio -
1Y Target Price 1.74
Price to earnings Ratio -
1Y Target Price 1.74
Volume (30-day avg) 2
Beta 1.56
52 Weeks Range 0.22 - 7.88
Updated Date 08/30/2025
52 Weeks Range 0.22 - 7.88
Updated Date 08/30/2025
Dividends yield (FY) 87.56%
Basic EPS (TTM) -0.57

Earnings Date

Report Date 2025-08-04
When Before Market
Estimate -0.17
Actual -0.0902

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -15.25%
Return on Equity (TTM) -21.25%

Valuation

Trailing PE -
Forward PE -
Enterprise Value -98265734
Price to Sales(TTM) -
Enterprise Value -98265734
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA -8.09
Shares Outstanding 47308400
Shares Floating 33355729
Shares Outstanding 47308400
Shares Floating 33355729
Percent Insiders 5.64
Percent Institutions 74.16

ai summary icon Upturn AI SWOT

ESSA Pharma Inc

stock logo

Company Overview

overview logo History and Background

ESSA Pharma Inc. is a pharmaceutical company focused on developing novel therapies for prostate cancer. Founded in 2009, it has progressed through preclinical and clinical stages with its lead drug candidate, accelerating the development of oncology treatments.

business area logo Core Business Areas

  • Androgen Receptor Signaling: ESSA Pharma Inc. is focused on disrupting androgen receptor signaling, a key driver of prostate cancer. This includes small molecule inhibitors targeting the N-terminal domain (NTD) of the androgen receptor.

leadership logo Leadership and Structure

ESSA Pharma Inc's leadership team includes a CEO, Chief Medical Officer, and other key executives overseeing research, development, and operations. The company has a board of directors providing strategic guidance.

Top Products and Market Share

overview logo Key Offerings

  • EPI-738: EPI-738 is ESSA Pharma's lead investigational product for prostate cancer. It is designed to block the N-terminal domain of the androgen receptor. Market share data is not yet applicable as the product is in clinical development. Competitors include developers of other androgen receptor inhibitors, like ARASENS, Janssen, and Orion. Clinical stage revenue.

Market Dynamics

industry overview logo Industry Overview

The prostate cancer treatment market is a substantial and growing sector of the pharmaceutical industry. The prevalence of prostate cancer and the increasing aging population are major drivers. Significant unmet needs exist for patients with advanced or resistant disease.

Positioning

ESSA Pharma is positioned as a developer of next-generation androgen receptor inhibitors. Its competitive advantage lies in its unique approach of targeting the N-terminal domain (NTD) of the AR, which differs from existing treatments.

Total Addressable Market (TAM)

The prostate cancer therapeutics market is projected to reach over $12 billion in the coming years. ESSA Pharma aims to capture a portion of this market by providing new treatment options for patients resistant to existing therapies.

Upturn SWOT Analysis

Strengths

  • Novel drug target (N-terminal domain of AR)
  • Strong intellectual property portfolio
  • Experienced management team
  • Potential for improved efficacy and safety profile

Weaknesses

  • Single product pipeline
  • Reliance on clinical trial outcomes
  • Limited financial resources compared to larger pharmaceutical companies
  • High regulatory risk

Opportunities

  • Positive clinical trial results leading to regulatory approval
  • Partnerships with larger pharmaceutical companies
  • Expansion into other cancer indications
  • Increasing prevalence of prostate cancer

Threats

  • Failure to achieve positive clinical trial results
  • Competition from established prostate cancer therapies
  • Changes in regulatory landscape
  • Patent challenges

Competitors and Market Share

competitor logo Key Competitors

  • JNJ
  • MRK
  • PFE

Competitive Landscape

ESSA Pharma's competitive advantage lies in its novel drug target, however it faces strong competition from established companies with significantly larger resources and existing market presence.

Growth Trajectory and Initiatives

Historical Growth: Historical growth has been primarily reflected in the advancement of its lead drug candidate through clinical trials.

Future Projections: Future growth is dependent on successful clinical trial outcomes, regulatory approvals, and potential commercialization or partnerships.

Recent Initiatives: Recent initiatives include advancing the Phase 1/2 clinical trial of EPI-738, securing additional funding, and expanding its intellectual property portfolio.

Summary

ESSA Pharma is a clinical-stage company with a promising novel drug target for prostate cancer. Its future hinges on the success of its clinical trials and its ability to secure partnerships or funding. The company faces significant risks due to its single product pipeline and reliance on clinical trial outcomes, but it is working to secure itself in the market.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • ESSA Pharma Inc. website
  • SEC filings
  • Industry reports
  • Clinical trial data

Disclaimers:

The information provided is for informational purposes only and does not constitute financial advice. Investment decisions should be made based on independent research and consultation with a qualified financial advisor.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About ESSA Pharma Inc

Exchange NASDAQ
Headquaters Vancouver, BC, Canada
IPO Launch date 2015-07-09
President, CEO & Director Dr. David Ross Parkinson M.D.
Sector Healthcare
Industry Biotechnology
Full time employees 35
Full time employees 35

ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company was incorporated in 2009 and is headquartered in Vancouver, Canada.